<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31473" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Zollinger-Ellison Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cho</surname>
            <given-names>Min S.</given-names>
          </name>
          <aff>McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Min Cho declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>11</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31473.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Zollinger-Ellison syndrome (ZES) is a group of symptoms comprised of severe peptic ulcer disease, gastroesophageal reflux disease (GERD), and chronic diarrhea caused by a gastrin-secreting tumor of the duodenum or pancreas (gastrinoma triangle) that results in increased stimulation of acid-secreting cells of the stomach. Zollinger-Ellison syndrome could impact the patient's quality of life and increase mortality if it is not recognized and treated. This activity covers the proper evaluation by the interprofessional team to provide effective treatment plans to lower mortality. This activity reviews the assessment and management of Zollinger-Ellison syndrome and the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the typical presentations associated with Zollinger-Ellison syndrome.</p></list-item><list-item><p>Identify the proper steps to diagnose Zollinger-Ellison syndrome.</p></list-item><list-item><p>Evaluate&#x000a0;the treatment options for Zollinger-Ellison syndrome.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among interprofessional team members to improve outcomes for patients with Zollinger-Ellison syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31473">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31473.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Zollinger-Ellison syndrome (ZES) is a group of&#x000a0;symptoms&#x000a0;comprised of severe peptic ulcer disease, gastroesophageal reflux disease, and chronic diarrhea caused by a gastrin-secreting tumor of the duodenum or pancreas (gastrinoma triangle) that results in increased stimulation of acid-secreting cells of the stomach.<xref ref-type="bibr" rid="article-31473.r1">[1]</xref><xref ref-type="bibr" rid="article-31473.r2">[2]</xref>&#x000a0;Gastrinoma is a functional neuroendocrine tumor&#x000a0;that&#x000a0;secretes&#x000a0;gastric acid, which causes&#x000a0;ZES (see <bold>Image.</bold> Gastrinoma on Distal Pancreas).<xref ref-type="bibr" rid="article-31473.r3">[3]</xref>&#x000a0;The earlier misconception was that the location of gastrinoma was in the&#x000a0;pancreas. However, gastrinomas occur in the duodenum more than the pancreas by&#x000a0;3 times, especially in the first&#x000a0;portion of the duodenum.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref>&#x000a0;There are other&#x000a0;non-neuroendocrine tumors&#x000a0;secreting gastrin, but not at a level to cause significant symptoms.<xref ref-type="bibr" rid="article-31473.r1">[1]</xref>&#x000a0;Gastrinoma-causing&#x000a0;ZES occurs sporadically in about 80% of cases and is reported to be 20% to 25% as multiple endocrine neoplasia&#x000a0;type&#x000a0;1 (MEN1) from multiple reports in the literature.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;Approximately 50% of patients with MEN1 have ZES; therefore, MEN1 must be included in a workup if the clinician suspects ZES.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref>&#x000a0;It takes an average of 8 years from the start of symptoms to diagnosis&#x000a0;due&#x000a0;to&#x000a0;the widespread use of&#x000a0;proton pump inhibitors (PPIs).<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;One study of&#x000a0;2 referral centers,&#x000a0;1 in Italy and&#x000a0;1 in the United States, showed a 62% decrease in referrals and diagnosis of ZES compared to when PPIs were used less frequently.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r6">[6]</xref>&#x000a0;ZES first appeared&#x000a0;in the Annals of Surgery in 1955 as a case series compiled by&#x000a0;2 surgeons from&#x000a0;Ohio State University,&#x000a0;Dr. Robert M. Zollinger and Edwin H. Ellison. Both cases had ulcers at the upper jejunum with excess gastric acid production refractory to medical and surgical therapy, including gastrectomy. The ultimate finding that led to ZES with hypersecretion, hyperacidity, and recurrent peptic ulceration was a non-beta cell islet tumor of the pancreas.<xref ref-type="bibr" rid="article-31473.r7">[7]</xref>&#x000a0;The pioneer case series induced enough interest to publish multiple studies recognizing the connections between gastrinoma&#x000a0;and ZES.</p>
      </sec>
      <sec id="article-31473.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>An ectopic neuroendocrine gastrin-secreting tumor that stimulates the acid-secreting cells of the stomach causes ZES. Gastrin results in gastrointestinal mucosal ulceration.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref></p>
      </sec>
      <sec id="article-31473.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>On top of the increased use of PPIs in modern times and the resultant difficulty in diagnosing&#x000a0;ZES early, only 0.1% to 1% of patients with peptic ulcer disease (PUD) have ZES.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r2">[2]</xref>&#x000a0;There is a report that an estimated 25% to 30% of patients with ZES have MEN1, a group of hyperplastic cells or tumors of the pituitary, parathyroid, and pancreatic islet cells. Therefore, patients with ZES from MEN1 could cause hypersecretion of gastric acid from hypercalcemia.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref><xref ref-type="bibr" rid="article-31473.r9">[9]</xref>&#x000a0;Epelboym and Mazeh, in 2014, presented the difficulty in estimating the incidence because of the overlap between ZES and PUD, and&#x000a0;an accurate incidence cannot&#x000a0;be determined. Still, gastrinomas are found in every 0.1 to 3 persons per million.<xref ref-type="bibr" rid="article-31473.r10">[10]</xref>&#x000a0;More females than males are developing ZES,&#x000a0;and all age groups reported having ZES.<xref ref-type="bibr" rid="article-31473.r10">[10]</xref><xref ref-type="bibr" rid="article-31473.r11">[11]</xref></p>
      </sec>
      <sec id="article-31473.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Most common symptoms, including abdominal pain, diarrhea, and heartburn, are caused by excess&#x000a0;gastrin secretion from gastrinoma.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;<xref ref-type="bibr" rid="article-31473.r12">[12]</xref>&#x000a0;Arnold described the trophic effect of excess gastrin as "increased fundic mucosal thickness, increased parietal cell mass, prominent gastric folds, and proliferation of gastric enterochromaffin-like cells."<xref ref-type="bibr" rid="article-31473.r12">[12]</xref>&#x000a0;Usually, gastric acid secretion is controlled&#x000a0;by negative feedback mechanisms by somatostatin released by gastric D cells to maintain gastric acid homeostasis and proper pH.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref>&#x000a0;However, due to unopposed gastrin release by the neuroendocrine tumor, gastrinoma results in severe PUD because of excess gastric acid secretion to the post-bulbar regions of the duodenum from the esophagus via the trophic effect of gastrin on enterochromaffin-like and parietal cells.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref><xref ref-type="bibr" rid="article-31473.r13">[13]</xref><xref ref-type="bibr" rid="article-31473.r14">[14]</xref></p>
      </sec>
      <sec id="article-31473.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common&#x000a0;symptom of&#x000a0;ZES is abdominal pain, followed by diarrhea and heartburn.&#x000a0;The patients can present initially with long periods of persistent symptoms due to unopposed gastrin secretion from a gastrinoma. Malabsorption&#x000a0;leads to hypersecretion of acid, and patients can present with weight loss and chronic diarrhea.<italic toggle="yes">&#x000a0;Helicobacter&#x000a0;pylori</italic> testing is negative; many patients continue to have symptoms despite taking PPIs.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r15">[15]</xref>&#x000a0;Because gastrinoma also presents as part of MEN1, some patients have a family history of endocrinopathy or some history of refractory PUD at an early age.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r15">[15]</xref><xref ref-type="bibr" rid="article-31473.r16">[16]</xref>&#x000a0;Examples of endocrinopathy include&#x000a0;hypercalcemia and kidney stones from parathyroid hyperplasia or neoplasm.</p>
      </sec>
      <sec id="article-31473.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>For&#x000a0;laboratory tests to accurately diagnose ZES, patients must stop using PPIs for at least&#x000a0;1 week or cease using H2-receptor antagonists for 48 hours.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;An&#x000a0;initial test involves measuring fasting serum gastrin levels. This test has 99% sensitivity, and patients with gastrinoma have a gastrin level greater than 100 pg/ml. The test is diagnostic if the level exceeds 1000 pg/ml.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r10">[10]</xref>&#x000a0;However, the fasting gastrin level can normalize after parathyroidectomy in patients with MEN1 and gastrinoma resection, even though the ZES&#x000a0;is not fully cured.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;Basal acid output test has 98% sensitivity and a level greater than 5 mEq per hour if the patient had gastrinoma resection or greater than 15 mEq per hour for those who did not. Gastric pH would be less than equal to 2. One can perform a&#x000a0;secretin stimulation test, which measures fasting serum gastrin level at 2 to 15 minutes after intravenous secretin administration. A level greater than or equal to 200 pg/ml&#x000a0;indicates ZES and has 85% to 87% sensitivity.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r10">[10]</xref>&#x000a0;If the clinician suspects ZES, screening for MEN1 needs to be performed by ordering serum calcium, parathyroid hormone level, prolactin, and pancreatic polypeptide.<xref ref-type="bibr" rid="article-31473.r10">[10]</xref> MEN1 is strongly suspected if patients have primary hyperparathyroidism, and parathyroidectomy is&#x000a0;recommended.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref></p>
        <p>Imaging studies&#x000a0;are recommended&#x000a0;to localize gastrinoma or to evaluate any metastases. Usually, noninvasive imaging is done to assess the extent of the primary tumor or metastases. Imaging&#x000a0;can locate the tumors before the surgery. CT and MRI detect up to 3 cm of mass but are unreliable if the mass is less than 3 cm. Somatostatin receptor scintigraphy is&#x000a0;known to be&#x000a0;more sensitive than conventional imaging studies, including CT and MRI, and has higher specificity to detect extrahepatic gastrinoma. Somatostatin receptor scintigraphy involves indium-labeled octreotide with a strong affinity for type 2 somatostatin receptors expressed on gastrinoma cells. Positron emission tomography is used to assess metastasis to other body organs. Invasive modalities include an endoscopic ultrasound to evaluate the pancreas more closely and an&#x000a0;esophagogastroduodenoscopy to assess any abnormalities visually.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r10">[10]</xref></p>
      </sec>
      <sec id="article-31473.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Before the&#x000a0;discovery of H2-receptor antagonists in the 1970s and PPIs in the 1980s, total gastrectomy was the only reasonable option to treat ZES.<xref ref-type="bibr" rid="article-31473.r1">[1]</xref> The dose&#x000a0;of PPIs such as oral omeprazole and intravenous pantoprazole must be adjusted to normalize basal acid output levels to less than 15 mEq per hour and less than 5 mEq per hour for those with prior surgery to decrease acid secretion. Eighty milligrams of pantoprazole by mouth twice daily is the typical dose. Patients should take this on an empty stomach.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref>&#x000a0;For those rare patients who cannot tolerate PPIs, an H2-receptor antagonist is an option.<xref ref-type="bibr" rid="article-31473.r1">[1]</xref>&#x000a0;Hyperparathyroidism from MEN1 causes hypercalcemia, which can exacerbate the symptoms because&#x000a0;hypercalcemia increases gastrin levels. Therefore, subtotal parathyroidectomy must precede the resection of the primary tumor, which can result in better symptom control and may normalize abnormal gastrin levels.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref>&#x000a0;Because patients with ZES and MEN1 have multiple tumors with a very&#x000a0;low&#x000a0;cure rate, a tumor is only resected if the size is greater than 2 cm.&#x000a0;Surgical exploration is an option in patients with sporadic gastrinomas because of&#x000a0;the high propensity for the tumor to&#x000a0;metastasize to the liver, lymph nodes, and distant organs. Those with advanced disease need interprofessional rounds for more nonsurgical options, including chemotherapy with everolimus, sunitinib, somatostatin analogs, interferon, chemoembolization,&#x000a0;radioembolization, and radiofrequency ablation.<xref ref-type="bibr" rid="article-31473.r1">[1]</xref><xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r10">[10]</xref></p>
      </sec>
      <sec id="article-31473.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis of hypergastrinemia includes vagotomy,&#x000a0;PUD secondary to&#x000a0;<italic toggle="yes">Helicobacter pylori</italic> infection, nonsteroidal&#x000a0;anti-inflammatory drugs use, gastric outlet obstruction, renal insufficiency, short bowel syndrome, and autoimmune gastritis (Type A).<xref ref-type="bibr" rid="article-31473.r8">[8]</xref><xref ref-type="bibr" rid="article-31473.r12">[12]</xref>&#x000a0;The etiology of peptic ulcers includes the overuse of nonsteroidal&#x000a0;anti-inflammatory drugs such as ibuprofen and aspirin. A clinician may be unable to distinguish abdominal pain from excess acids and ulcers from PUD and ZES, but ZES causes more diarrhea and esophageal disease.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref>&#x000a0;<italic toggle="yes">Helicobacter pylori</italic> produces urease, which acts near G cells&#x000a0;and&#x000a0;causes urea hydrolysis and alkalization, affecting D cells and&#x000a0;diminishing somatostatin cell release secondary to inflammation. Gastric outlet obstruction causes antral distention, which activates parietal cells via acetylcholine.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref>&#x000a0;Patients with chronic kidney disease or end-stage&#x000a0;renal disease and undergoing dialysis have elevated serum gastrin. Gastrin clears through the kidney, and renal insufficiency prevents the kidney from working properly. One study revealed&#x000a0;increased gastric cell growth in a rat model with uremia resulting from proton back diffusion in the stomach, causing less mucosal barrier protection.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref><xref ref-type="bibr" rid="article-31473.r17">[17]</xref><xref ref-type="bibr" rid="article-31473.r18">[18]</xref><xref ref-type="bibr" rid="article-31473.r19">[19]</xref>&#x000a0;Gastric outlet obstruction causes distension of the antrum, which activates parietal cells via acetylcholine and produces hypergastrinemia.<xref ref-type="bibr" rid="article-31473.r8">[8]</xref></p>
      </sec>
      <sec id="article-31473.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Because&#x000a0;ZES involves gastrinoma, one must evaluate the prognosis-based cancer stage. About 60% to 90% of gastrinomas are malignant with metastasis to the lymph nodes, liver, or distant organs. Fifty percent of pancreatic gastrinomas have a 50% incidence, and 10% of duodenal gastrinomas have a 10% incidence in the liver.&#x000a0;Metastasis to the liver directly affects overall survival as pancreatic gastrinomas have lower long-term survival rates than duodenal gastrinomas. The patients with liver metastases have a 15% 10-year survival after the surgery, but those without liver metastases have a 95% 20-year survival, which is a significant finding.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref>&#x000a0;On the other hand, duodenal gastrinomas have a higher incidence of lymph node metastases than pancreatic gastrinomas, 70% versus 40%, respectively. However, lymph node involvement did not&#x000a0;show a decrease in survival without liver metastases.<xref ref-type="bibr" rid="article-31473.r4">[4]</xref><xref ref-type="bibr" rid="article-31473.r20">[20]</xref><xref ref-type="bibr" rid="article-31473.r21">[21]</xref></p>
      </sec>
      <sec id="article-31473.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications from acid secretion&#x000a0;consist of&#x000a0;bleeding and perforation of GI tracts, including the esophagus, stomach, and duodenum.<xref ref-type="bibr" rid="article-31473.r5">[5]</xref><xref ref-type="bibr" rid="article-31473.r15">[15]</xref>&#x000a0;Significant complications include death from surgery when the plan is to remove gastrinoma or other cancers from MEN1.</p>
      </sec>
      <sec id="article-31473.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Clinicians must educate patients to comply with taking PPIs to control the symptoms of ZES. Patients must not only take medications as instructed but follow up for laboratory tests to assess the effectiveness of the&#x000a0;medications. This is very important to reduce the recurrence and complications from ZES. Although the cure rate, especially with MEN1, is low, patients must be encouraged to follow up with their clinicians and seek help.</p>
      </sec>
      <sec id="article-31473.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>ZES&#x000a0;is caused by gastrinoma, which causes trophic effects from gastrin hypersecreting gastric acid. It can cause severe abdominal pain from multiple ulcers in the esophagus, stomach, and duodenum, diarrhea, and heartburn. PPIs have been the main therapy to control the symptoms. MEN1 is associated with ZES due to&#x000a0;gastrinoma being a part of MEN1. However, the cure rate is low, and surgical resection is not ideal. If surgical exploration is indicated, managing hyperparathyroidism, including subtotal parathyroidectomy, must precede actual gastrinoma resection to control symptoms. There is a high propensity of sporadic gastrinoma metastasizing to the liver and lymph nodes, and&#x000a0;a surgeon must evaluate distant organs and those found to have sporadic gastrinoma for surgery. If the disease has already metastasized and the patient is not a surgical candidate, there are multiple options, including embolizations and chemotherapy.</p>
      </sec>
      <sec id="article-31473.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional communication between primary care clinicians, gastroenterologists, surgeons, oncologists, pharmacists, nurses, and laboratory personnel is necessary for professionals to stay on the same page in treating ZES. Diagnosing ZES can be challenging with the wide use of PPIs for heartburn. Still, patients may suffer from unexplained chronic diarrhea, malabsorption, and even dysphagia from esophagus damage secondary to excess gastric acid secretion. Nurses can assist in patient evaluation, administer medications, and answer patient questions regarding their condition. Pharmacists ensure appropriate dosing, perform medication reconciliation and counsel the patient on their medication regimen. All interprofessional team members must report any concerns to other team members for corrective interventions. If patients have difficulty coping with situations that endanger their social lives, an interprofessional approach with a social worker and a case manager is needed. Because&#x000a0;ZES is&#x000a0;challenging to cure, patients must stay on PPIs to control symptoms, which could be daunting. Continuous support must entail support from medical professionals, close family members, and friends.</p>
      </sec>
      <sec id="article-31473.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31473&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31473">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/gut-health/zollinger-ellison-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=31473">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31473/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31473">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-31473.s16">
        <fig id="article-31473.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Gastrinoma on Distal Pancreas Contributed by&#x000a0;S Bhimji, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="gastrinoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-31473.s17">
        <title>References</title>
        <ref id="article-31473.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Norton</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Gastrinomas: Medical or Surgical Treatment.</article-title>
            <source>Endocrinol Metab Clin North Am</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>577</fpage>
            <page-range>577-601</page-range>
            <pub-id pub-id-type="pmid">30098717</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Cingam</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Botejue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoilat</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Karanchi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <chapter-title>Gastrinoma</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">28722872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Feigenbaum</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Koviack</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ojeaburu</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2001</year>
            <month>May</month>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>189</fpage>
            <page-range>189-222</page-range>
            <pub-id pub-id-type="pmid">11388095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krampitz</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Norton</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Current management of the Zollinger-Ellison syndrome.</article-title>
            <source>Adv Surg</source>
            <year>2013</year>
            <volume>47</volume>
            <fpage>59</fpage>
            <page-range>59-79</page-range>
            <pub-id pub-id-type="pmid">24298844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>454</fpage>
            <page-range>454-63</page-range>
            <pub-id pub-id-type="pmid">15527675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Corleto</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Annibale</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Angeletti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Delle Fave</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome?</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1555</fpage>
            <page-range>1555-61</page-range>
            <pub-id pub-id-type="pmid">11563994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ZOLLINGER</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>ELLISON</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas.</article-title>
            <source>Ann Surg</source>
            <year>1955</year>
            <month>Oct</month>
            <volume>142</volume>
            <issue>4</issue>
            <fpage>709</fpage>
            <page-range>709-23; discussion, 724-8</page-range>
            <pub-id pub-id-type="pmid">13259432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Phan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benhammou</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Pisegna</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Gastric Hypersecretory States: Investigation and Management.</article-title>
            <source>Curr Treat Options Gastroenterol</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>386</fpage>
            <page-range>386-97</page-range>
            <pub-id pub-id-type="pmid">26342486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Pieterman</surname>
                <given-names>CRC</given-names>
              </name>
              <name>
                <surname>van Leeuwaarde</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>van den Broek</surname>
                <given-names>MFM</given-names>
              </name>
              <name>
                <surname>van Nesselrooij</surname>
                <given-names>BPM</given-names>
              </name>
              <name>
                <surname>Valk</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <chapter-title>Multiple Endocrine Neoplasia Type 1</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Anawalt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Blackman</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Boyce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chrousos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Corpas</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Dhatariya</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dungan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hofland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kalra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kaltsas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kapoor</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kopp</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Korbonits</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kuohung</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Laferr&#x000e8;re</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>McLachlan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>New</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sahay</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sperling</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Stratakis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Trence</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <source>Endotext [Internet]</source>
            <publisher-name>MDText.com, Inc.</publisher-name>
            <publisher-loc>South Dartmouth (MA)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">29465925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Epelboym</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mazeh</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Zollinger-Ellison syndrome: classical considerations and current controversies.</article-title>
            <source>Oncologist</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-50</page-range>
            <pub-id pub-id-type="pmid">24319020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berna</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>295</fpage>
            <page-range>295-330</page-range>
            <pub-id pub-id-type="pmid">17108778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and differential diagnosis of hypergastrinemia.</article-title>
            <source>Wien Klin Wochenschr</source>
            <year>2007</year>
            <volume>119</volume>
            <issue>19-20</issue>
            <fpage>564</fpage>
            <page-range>564-9</page-range>
            <pub-id pub-id-type="pmid">17985088</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisegna</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holtmann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Howden</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Spechler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Triadafilopoulos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tytgat</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Review article: oesophageal complications and consequences of persistent gastro-oesophageal reflux disease.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>20 Suppl 9</volume>
            <issue>Suppl 9</issue>
            <fpage>47</fpage>
            <page-range>47-56</page-range>
            <pub-id pub-id-type="pmid">15527464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pisegna</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>1999</year>
            <month>Dec</month>
            <volume>1</volume>
            <issue>6</issue>
            <fpage>511</fpage>
            <page-range>511-7</page-range>
            <pub-id pub-id-type="pmid">10980995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shojamanesh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Abou-Saif</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Peghini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Doppman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Zollinger-Ellison syndrome. Clinical presentation in 261 patients.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-411</page-range>
            <pub-id pub-id-type="pmid">11144036</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1.</article-title>
            <source>J Intern Med</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>243</volume>
            <issue>6</issue>
            <fpage>477</fpage>
            <page-range>477-88</page-range>
            <pub-id pub-id-type="pmid">9681846</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGowan</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Cover</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Blaser</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Helicobacter pylori and gastric acid: biological and therapeutic implications.</article-title>
            <source>Gastroenterology</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>110</volume>
            <issue>3</issue>
            <fpage>926</fpage>
            <page-range>926-38</page-range>
            <pub-id pub-id-type="pmid">8608904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quintero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ohning</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Del Rivero</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Guth</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Gastrin mediates the increase in gastric cell growth in uremic rats.</article-title>
            <source>Am J Physiol</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>268</volume>
            <issue>4 Pt 1</issue>
            <fpage>G586</fpage>
            <page-range>G586-91</page-range>
            <pub-id pub-id-type="pmid">7733285</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quintero</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kaunitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nishizaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>De Giorgio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sternini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guth</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>Uremia increases gastric mucosal permeability and acid back-diffusion injury in the rat.</article-title>
            <source>Gastroenterology</source>
            <year>1992</year>
            <month>Dec</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>1762</fpage>
            <page-range>1762-8</page-range>
            <pub-id pub-id-type="pmid">1451970</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sutliff</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Doppman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Gibril</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Venzon</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Serrano</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.</article-title>
            <source>J Clin Oncol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>2420</fpage>
            <page-range>2420-31</page-range>
            <pub-id pub-id-type="pmid">9196158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31473.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roland</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Bian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mansour</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Yopp</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Balch</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>XJ</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Survival impact of malignant pancreatic neuroendocrine and islet cell neoplasm phenotypes.</article-title>
            <source>J Surg Oncol</source>
            <year>2012</year>
            <month>May</month>
            <volume>105</volume>
            <issue>6</issue>
            <fpage>595</fpage>
            <page-range>595-600</page-range>
            <pub-id pub-id-type="pmid">22006521</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
